Literature DB >> 17881233

Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.

Akio Nakamura1, Tetsuhiro Yamada, Tetsuo Asaki.   

Abstract

N-Acylsulfonamide and N-acylsulfonylurea derivatives of the carboxylic acid prostacyclin receptor agonist 1 were synthesized and their potential as prodrug forms of the carboxylic acid was evaluated in vitro and in vivo. These compounds were converted to the active compound 1 by hepatic microsomes from rats, dogs, monkeys, and humans, and some of the compounds were shown to yield sustained plasma concentrations of 1 when they were orally administered to monkeys. These types of analogues, including NS-304 (2a), are potentially useful prodrugs of 1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881233     DOI: 10.1016/j.bmc.2007.08.052

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

Review 1.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

2.  Synthesis of novel IP agonists via N-aminoethyl cyclic amines prepared by decarboxylative ring-opening reactions.

Authors:  Yasuhiro Morita; Takeshi Ishigaki; Kuniaki Kawamura; Ryoji Hayashi; Masafumi Isogaya; Mika Kitsukawa; Mitsuko Miyamoto; Masashi Uchida; Katsuhiko Iseki
Journal:  Molecules       Date:  2012-01-31       Impact factor: 4.411

3.  The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.

Authors:  Yohei Honda; Keiji Kosugi; Chiaki Fuchikami; Kazuya Kuramoto; Yuki Numakura; Keiichi Kuwano
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.